Future trends in global convergence for cell and gene therapy regulation Future Trends in Global Convergence for Cell and Gene Therapy Regulation Introduction to Cell and Gene Therapy Regulations The emergence of cell and gene therapies has revolutionized the treatment landscape for various diseases, particularly genetic disorders and cancers. As these novel therapies continue to develop, regulatory frameworks must adapt and evolve. Understanding the regulatory environments in different regions—including the United States (US), European Union (EU), and the United Kingdom (UK)—is essential for professionals involved in the development and approval of Advanced Therapy Medicinal Products (ATMPs) and Cell and Gene…

Tools to Track Evolving ATMP and CGT Guidance in Multiple Jurisdictions As the landscape of cell and gene therapies (CGT) continues to evolve rapidly in the pharmaceutical and biotechnology sectors, understanding the regulatory frameworks surrounding advanced therapy medicinal products (ATMPs) becomes increasingly complex. This article serves as a comprehensive guide, offering regulatory, CMC, clinical, and quality assurance leaders an in-depth step-by-step tutorial on tracking changing guidance across the US FDA, EMA, and MHRA jurisdictions. We will explore the nuances of ATMPs and CGT regulatory alignment, classification, and the implications of regulatory mechanisms like PRIME and RMAT, while also considering critical…

Managing Divergent Regulatory Feedback on CGT Endpoints and Comparators Cell and Gene Therapies (CGTs) represent a transformative area of medicine, offering potential cures for previously intractable diseases. However, the regulatory landscape for CGTs, especially concerning Advanced Therapy Medicinal Products (ATMPs), can be complex and divergent across jurisdictions. This article aims to provide a comprehensive tutorial on navigating divergent regulatory feedback associated with CGT endpoints and comparators, focusing on regulatory alignment between the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). Understanding the Regulatory Framework for ATMPs and…

Governance for Cross-Regional CGT Regulatory Steering Committees The field of cell and gene therapy (CGT) is evolving rapidly, presenting both significant opportunities and regulatory challenges across multiple regions. As regulatory leaders in the United States (US), Europe (EU), and the United Kingdom (UK) engage with advanced therapy medicinal products (ATMPs), establishing effective governance structures for cross-regional regulatory steering committees is paramount. This comprehensive tutorial outlines essential steps and considerations for navigating the complexities of ATMP classification and alignment of regulatory strategies among the US FDA, the European Medicines Agency (EMA), and the Medicines and Healthcare products Regulatory Agency (MHRA). By…

Global Safety Database and Risk Management Plan Design for CGT Portfolios Global Safety Database and Risk Management Plan Design for CGT Portfolios Cell and gene therapies (CGT) represent a significant advancement in the treatment of previously intractable diseases. As these therapies move through the continuum from development to marketing authorization, the need for robust regulatory frameworks is paramount. This regulatory tutorial offers a comprehensive examination of the design of global safety databases and risk management plans (RMP) for CGT portfolios, focusing on the alignment between the US FDA, European Medicines Agency (EMA), and the UK’s Medicines and Healthcare products Regulatory…